BERKELEY, CA--(Marketwired - May 6, 2013) - Dynavax Technologies Corporation (
For the quarter ended March 31, 2013, Dynavax reported total revenues of $2.1 million compared to $2.4 million for the quarter ended March 31, 2012. Grant revenue from the Company's contract for adjuvant development awarded by the National Institutes of Health declined by $0.4 million from the prior year.
Research and development expenses for the quarter ended March 31, 2013 of $14.2 million increased by $1.8 million from the first quarter of 2012. This increase was due primarily to the purchase of a HEPLISAV™ component as well as severance expenses, including non-cash stock-based compensation charges.
General and administrative expenses for the quarter ended March 31, 2013 of $8.8 million increased by $3.0 million from the first quarter of 2012. This increase resulted primarily from incremental severance expenses, including non-cash stock-based compensation charges.
About HEPLISAV
HEPLISAV is an investigational adult hepatitis B vaccine for which US and European licensure applications have been accepted for review by the FDA and the EMA. Dynavax plans to meet with the FDA in June to discuss the most expeditious path to approval for HEPLISAV, following the Complete Response Letter issued in February 2013. Dynavax has worldwide commercial rights to HEPLISAV, which combines hepatitis B surface antigen with a proprietary Toll-like Receptor 9 agonist to enhance the immune response.
About Dynavax
Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. The Company's lead product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine. For more information visit www.dynavax.com .
Forward-Looking Statements
This press release contains "forward-looking" statements. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in our business, including our meeting and plans for discussions with the FDA; whether successful clinical and regulatory development and review and approval of HEPLISAV and our process for its manufacture can occur without significant delay or additional studies; whether our studies and manufacturing efforts can support registration for commercialization of HEPLISAV; the results of clinical trials and the impact of those results on the initiation and completion of subsequent trials and issues arising in the regulatory process, including whether the BLA and the European licensure application will be approved; our ability to obtain additional financing to support the development and commercialization of HEPLISAV and our other operations; possible claims against us, including enjoining sales of HEPLISAV, based on the patent rights of others; and other risks detailed in the "Risk Factors" section of our current periodic reports with the SEC. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. Information on Dynavax's website at www.dynavax.com is not incorporated by reference in our current periodic reports with the SEC.
- tables to follow -
| DYNAVAX TECHNOLOGIES CORPORATION | |||||||||
| CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||
| (In thousands, except per share amounts) | |||||||||
| (Unaudited) | |||||||||
| Three Months Ended March 31, | |||||||||
| 2013 | 2012 | ||||||||
| Revenues: | |||||||||
| Collaboration revenue | $ | 883 | $ | 929 | |||||
| Grant revenue | 760 | 1,087 | |||||||
| Service and license revenue | 442 | 334 | |||||||
| Total revenues | 2,085 | 2,350 | |||||||
| Operating expenses: | |||||||||
| Research and development | 14,164 | 12,405 | |||||||
| General and administrative | 8,800 | 5,793 | |||||||
| Total operating expenses | 22,964 | 18,198 | |||||||
| Loss from operations | (20,879 | ) | (15,848 | ) | |||||
| Interest income | 72 | 52 | |||||||
| Interest expense | (32 | ) | (587 | ) | |||||
| Other income (expense) | 14 | (122 | ) | ||||||
| Net loss | $ | (20,825 | ) | $ | (16,505 | ) | |||
| Basic and diluted net loss per share | $ | (0.11 | ) | $ | (0.11 | ) | |||
| Shares used to compute basic and diluted net loss per share | 182,847 | 155,431 | |||||||
| DYNAVAX TECHNOLOGIES CORPORATION | |||||||
| SELECTED CONSOLIDATED BALANCE SHEET DATA | |||||||
| (In thousands) | |||||||
| (Unaudited) | |||||||
| March 31, | December 31, | ||||||
| 2013 | 2012 | ||||||
| Assets | |||||||
| Cash, cash equivalents and marketable securities | $ | 105,373 | $ | 125,130 | |||
| Property and equipment, net | 7,972 | 7,965 | |||||
| Goodwill | 2,400 | 2,475 | |||||
| Other assets | 3,876 | 4,182 | |||||
| Total assets | $ | 119,621 | $ | 139,752 | |||
| Liabilities and stockholders' equity | |||||||
| Deferred revenues | $ | 11,180 | $ | 12,068 | |||
| Other liabilities | 10,514 | 12,858 | |||||
| Total liabilities | 21,694 | 24,926 | |||||
| Stockholders' equity | 97,927 | 114,826 | |||||
| Total liabilities and stockholders' equity | $ | 119,621 | $ | 139,752 | |||
Contacts: Jennifer Lew Vice President, Finance 510-665-7217 Email Contact Michael Ostrach Vice President and Chief Business Officer 510-665-7257 Email Contact
